Skip to main content
Year archive

Swedish Orphan Biovitrum — 2022 filings

All 23 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2022, sourced directly from the official regulator.

23 Filings
2022 Period
2022 filings (23)
Filing Released Lang
Bo Jesper Hansen föreslås till ny styrelseordförande i Swedish Orphan Biovitrum AB (publ) inför årsstämman 2023
Board/Management Information
2022-11-18 Swedish
Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023
Board/Management Information
2022-11-18 English
Swedish Orphan Biovitrum AB (publ):s styrelseordförande Håkan Björklund står inte till förfogande för omval vid årsstämman 2023
Board/Management Information
2022-10-31 Swedish
Swedish Orphan Biovitrum AB (publ)’s Chairman of the Board Håkan Björklund will not be available for re-election at the Annual General Meeting 2023
Board/Management Information
2022-10-31 English
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-10-27 Swedish
Earnings Release 2022
Earnings Release 9M 2022
2022-10-27 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2022-09-30 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2022-09-30 English
Earnings Release 2022
Earnings Release H1 2022
2022-07-19 Swedish
Earnings Release 2022
Earnings Release H1 2022
2022-07-19 English
Sobi to license loncastuximab tesirine from ADC Therapeutics
Capital/Financing Update
2022-07-08 English
Sobi licensierar loncastuximab tesirine från ADC Therapeutics
Regulatory Filings
2022-07-08 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-28 Swedish
Earnings Release 2022
Earnings Release Q1 2022
2022-04-28 English
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-04-05 Swedish
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2022-04-05 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2022-04-05 Swedish
Efanesoctocog alfa uppnådde primära och huvudsakliga sekundära effektmått i en pivotal hemofili A-studie, och visade överlägsenhet jämfört med tidigare profylaktisk faktorbehandling
Regulatory Filings
2022-03-09 Swedish
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Earnings Release FY 2022
2022-03-09 English
Gamifant (emapalumab) rekommenderas godkännande i Kina för behandling av primär hemofagocyterande lymfohistiocytos (HLH)
Regulatory Filings
2022-02-25 Swedish
Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)
Regulatory Filings
2022-02-25 English
Earnings Release 2021
Earnings Release Q4 2021
2022-02-10 Swedish
Earnings Release 2021
Earnings Release Q4 2021
2022-02-10 English